How can the clinical picture guide appropriate laboratory drug testing in the treatment of pain clinic patients with opioid analgesics?

Pain Medicine (United States)

Volumn 13, Issue 7, 2012, Pages 857-859

  Abadie, Jude ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; OXYMORPHONE; PETHIDINE;

CLINICAL ASSESSMENT TOOL; DRUG SCREENING; EDITORIAL; HUMAN; LABORATORY TEST; PAIN; POINT OF CARE TESTING; TREATMENT OUTCOME; URINE DRUG TESTING;

EID: 84863870085     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01421.x     Document Type: Editorial

References (7)

1. Peppin JF, Passik SD, Couto JE, etal. Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain. Pain Med 2012;13(7):886-96.
2. Magnani B. Concentrations of compounds that produce positive results. In: Shaw L, Kwong T, eds. The Clinical Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation. Washington, DC: AACC Press; 2010:482-97.
3. Yang JM. Toxicology and drugs of abuse testing at the point of care. Clin Lab Med 2001;21:363-74, ix-x.
4. Fenton JJ. Toxicology: A Case-Oriented Approach. Boca Raton, FL: CRC Press; 2002.
5. Jenkins AJ. Forensic drug testing. In: Levine B, ed. Principles of Forensic Toxicology. Washington, DC: AACC Press; 1999:31-45.
6. Pesce A, West C, Egan City K, Strickland J. Interpretation of urine drug testing in pain patients. Pain Med 2012;13(7):868-85.
7. Lötsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82-9.